SPMO241220P92000
- 0.40
- 0.000.00%
Invesco S&P 500 Momentum Etf Newsroom
Trump Taps Sriram Krishnan As Senior AI Advisor — Elon Musk Agrees New David Sacks Underling 'Right Man For The Topic And The Time'
Express News | Nvidia Plans to Set up Taiwan Headquarters, Local Media Commercial Times Reports
'Sonic the Hedgehog 3' Races Past 'Mufasa: The Lion King' for First Place at Box Office
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Quantum Computing: The New AI? A Look at the Rapidly Expanding Market and Top Stocks For 2025
Insider Trades: Berkshire Adds OXY, Nvidia & Salesforce Among Notable Names This Week
Tech Titans Triumph: The Top 10 Billionaires Who Made Big Gains In 2024
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Apple's Home Strategy Has Struggled. Could That Change?
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Deal Dispatch: Honeywell, Textron And Soho House Are Making M&A Moves
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.
As Quantum Computing Stocks Soar, Wall Street Analysts Take Bullish Stance
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup
Notable Analyst Calls This Week: Tesla, Zoom and Micron Stocks Among Top Picks
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
Options Market Statistics: Tesla's Rollercoaster Week Ends with Friday Sell-Off; Options Pop
Invesco S&P 500 Momentum Etf To Go Ex-Dividend On December 23rd, 2024 With 0.1927 USD Dividend Per Share
Weekly Buzz: It was a rough week just before the Winter Solstice